14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Mon, 6 May 2024

Trading levels for NKTR

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 1.81 15.29 %
R2 1.74 10.66 %
R1 1.69 7.81 %
Current price: 1.57
Support S1 1.55 -1.44 %
S2 1.50 -4.29 %
S3 1.43 -8.92 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 1.67 6.37 %
R2 1.65 5.10 %
R1 1.58 0.637 %
Current price 1.57
Support S1 1.35 -14.01%
S2 1.32 -15.92%
S3 1.29 -17.83%

NKTR Predictions History

4 years ago
ThomasTissot123881 predicted that NKTR for 2019-10-14 is going

Rank:

4 years ago
Chaser predicted that NKTR for 2019-09-05 is going $17.68 (1.78%)

4 years ago
Chaser predicted that NKTR for 2019-09-03 is going $17.73 (4.85%)

4 years ago
Chaser predicted that NKTR for 2019-08-30 is going $18.05 (2.73%)

4 years ago
Chaser predicted that NKTR for 2019-08-12 is going $18.30 (-1.51%)

4 years ago
Chaser predicted that NKTR for 2019-06-20 is going $36.17 (2.20%)

4 years ago
Chaser predicted that NKTR for 2019-06-10 is going $32.64 (-1.09%)

4 years ago
Chaser predicted that NKTR for 2019-06-05 is going $33.25 (-1.16%)

4 years ago
Chaser predicted that NKTR for 2019-05-21 is going $31.76 (-4.97%)

4 years ago
Chaser predicted that NKTR for 2019-05-20 is going $31.27 (-2.34%)

Click to get the best stock tips daily for free!

About Nektar Therapeutics

Nektar Therapeutics Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and a... NKTR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT